MedPath

Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy

Not Applicable
Completed
Conditions
Enteropathy
Interventions
Dietary Supplement: High-dose Zinc
Drug: Placebo
Registration Number
NCT01440608
Lead Sponsor
Washington University School of Medicine
Brief Summary

The purpose of this study is to investigate the therapeutic effectiveness of high-dose zinc therapy and de-worming albendazole as separate interventions in restoring normal gut absorptive and immunological function as measured by the dual sugar permeability test and additional biomarkers in 1-3 year old rural Malawian children at high risk for Environmental Enteropathy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
225
Inclusion Criteria
  • 1-3 years of age
  • Lives in study villages
Exclusion Criteria
  • Unable to drink 100 mL of sugar water
  • Demonstrating evidence of severe acute malnutrition, WHZ < or = -3, presence of bi-pedal pitting edema
  • Apparent need for acute medical treatment for an illness or injury
  • Parent refusal to participate and return for 7-week follow-up

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Zinc therapyHigh-dose ZincHigh-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
PlaceboPlaceboPlacebo will be given for 14 days
AlbendazoleAlbendazoleAlbendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
Primary Outcome Measures
NameTimeMethod
Changes in urine lactulose:mannitol (L:M) ratio following therapy course.4 weeks, 7 weeks
Secondary Outcome Measures
NameTimeMethod
Change in blood endoCAb7 weeks
Change in fecal calprotectin mRNA4 weeks, 7 weeks

Trial Locations

Locations (1)

Saint Louis Nutrition Project

🇲🇼

Blantyre, Malawi

© Copyright 2025. All Rights Reserved by MedPath